Literature DB >> 9973163

Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection.

G Ghilardi1, J J Gonvers, A So.   

Abstract

Interferon alpha (IFN-alpha) therapy is associated with a number of immunological side-effects, including autoimmune diseases and a 10% prevalence of thyroiditis. Hepatitis C virus (HCV) infection itself predisposes to autoimmune phenomena including hypothyroidism and myositis. The development of clinical hypothyroidism in the presence of positive thyroid antibodies in patients infected with HCV and treated with IFN-alpha suggests a possible association between the viral disease and the therapy. HCV infection may predispose to autoimmune thyroid disease and IFN-alpha therapy may secondarily lead to the development of thyroid dysfunctions. We report the single case of a female patient who developed a severe proximal myopathy in conjunction with primary hypothyroidism (Hoffmann's syndrome) secondarily to IFN-alpha therapy for HCV infection. This case highlights the need for careful clinical and biological monitoring for potential side-effects in such patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9973163     DOI: 10.1093/rheumatology/37.12.1349

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  3 in total

1.  Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction.

Authors:  Omar Khokhar; Christopher Gange; Stephen Clement; James Lewis
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 2.  Endocrine and liver interaction: the role of endocrine pathways in NASH.

Authors:  Paola Loria; Lucia Carulli; Marco Bertolotti; Amedeo Lonardo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

3.  Uncommon presentation of a common disorder.

Authors:  P R Sowmini; M Jawahar; K Bhanu
Journal:  Ann Indian Acad Neurol       Date:  2013-01       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.